Breaking Finance News

Oddo Seydler Bank AG recorded STRATEC Biomedical (ETR:SBS), bumping up its stock price target to 56.00EUR today

Only yesterday STRATEC Biomedical (ETR:SBS) traded -1.07% lower at 50.76EUR. STRATEC Biomedical’s 50-day average is 9.16EUR and its two hundred day average is 8.16EUR. The last close is up 13.49% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time. 1,522,310 shares of STRATEC Biomedical exchanged hands, down from an avg. volume of 2,024,700

STRATEC Biomedical (ETR:SBS) had its target price raised to 56.00EUR by Oddo Seydler Bank AG in a report released Sunday October 02, 2016. The new target price indicates a possible upside of 0.10% based on the company's last stock close price.

Previously on 10/01/2016, Oddo Seydler Bank AG reported about STRATEC Biomedical (ETR:SBS) raised the target price from 0.00EUR to 56.00EUR. At the time, this indicated a possible upside of 0.10%.

Recent Performance Chart

STRATEC Biomedical (ETR:SBS)

STRATEC Biomedical has P/E ratio of 15.59 with a 52 week low of 3.98EUR and a 52 week high of 9.83EUR and has a market capitalization of 0 EUR.

In addition to Oddo Seydler Bank AG reporting its stock price target, a total of 3 analysts have released a report on STRATEC Biomedical. The 12-month target price is 28.48EUR with zero equity analysts rating the stock a strong buy, 0 analysts rating the company a buy, zero equity analysts rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 equity analysts rating the company a sell.

General Company Details For STRATEC Biomedical (ETR:SBS)

STRATEC Biomedical AG (STRATEC) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics. STRATEC's partners market Company's products to pharmaceutical laboratories, blood banks and research institutes throughout the world. STRATEC Group operats through its four consolidated subsidiaries in Switzerland, the United Kingdom, Germany as well as the United States, comprising STRATEC Biomedical Switzerland AG, STRATEC Biomedical UK, Ltd, STRATEC Molecular GmbH and STRATEC Biomedical USA, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.